Relationships between adrenal insufficiency and cardiovascular outcomes in patients with atrial fibrillation, atrial flutter and paroxysmal supraventricular tachycardia

Curr Probl Cardiol. 2024 Aug;49(8):102641. doi: 10.1016/j.cpcardiol.2024.102641. Epub 2024 May 15.

Abstract

Background: Patients with Adrenal Insufficiency (AI) face elevated cardiovascular risks, but little remains known about arrhythmia outcomes in this context.

Method: Analyzing the 2016-2019 Nationwide Inpatient Sample, we identified cases of Atrial Fibrillation, Atrial Flutter, and paroxysmal supraventricular tachycardia (PSVT) with a secondary diagnosis of AI. Mortality was the primary outcome while vasopressors and/or mechanical ventilation use, length of stay (LOS), and total hospitalization charges (THC) constituted secondary outcomes. Multivariate linear and logistic regression models were used to adjust for confounders.

Results: Among patients with Atrial Fibrillation, Atrial Flutter, and PSVT (N=1,556,769), 0.2% had AI. AI was associated with higher mortality (adjusted OR [aOR] 2.29, p=0.001), vasopressor and/or mechanical ventilation use (aOR 2.54, p<0.001), THC ($62,347 vs. $41,627, p<0.001) and longer LOS (4.4 vs. 3.2 days, p<0.001) compared to no AI.

Conclusion: AI was associated with higher adverse outcomes in cases of Atrial Fibrillation, Atrial Flutter, and PSVT.

Keywords: Adrenal insufficiency; Atrial fibrillation; Supraventricular arrythmia.

Publication types

  • Multicenter Study
  • Review

MeSH terms

  • Adrenal Insufficiency* / diagnosis
  • Adrenal Insufficiency* / epidemiology
  • Aged
  • Atrial Fibrillation* / epidemiology
  • Atrial Fibrillation* / therapy
  • Atrial Flutter* / epidemiology
  • Atrial Flutter* / therapy
  • Female
  • Humans
  • Length of Stay / statistics & numerical data
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Tachycardia, Paroxysmal / diagnosis
  • Tachycardia, Paroxysmal / physiopathology
  • Tachycardia, Paroxysmal / therapy
  • Tachycardia, Supraventricular* / diagnosis
  • Tachycardia, Supraventricular* / epidemiology
  • Tachycardia, Supraventricular* / etiology
  • Tachycardia, Supraventricular* / therapy
  • United States / epidemiology